RMTI Earnings

RMTI reported its earnings on 2026-03-23, showcasing a revenue of against an estimate of 18.56M, resulting in a 0% surprise. The EPS was 0, surpassing the expected 0.04 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following RMTI's earnings announcement on 2026-03-23, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, RMTI's stock price tends to shift by an average of 1.63% in the 10 days leading up to earnings and 7.5% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate RMTI's annual revenue to reach 16.55M, while the EPS is projected at -0.04. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates unchanged by 0% over the past three months, indicating analyst expectation in the company's performance.

The correlation between RMTI's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved unchanged by 0%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, RMTI's stock price typically moves by 1.63% in the 10 days before its earnings and 7.5% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of -0.04 and revenue of 16.55M.

The earnings call summary highlights significant challenges: a sharp decrease in gross profit and margins, a transition with the largest customer, and restructuring costs leading to net losses. Despite a positive cash position and potential growth in high-margin products, the weak financial performance and lack of immediate guidance present concerns. The Q&A provides some optimism with potential acquisitions and growth in the bicarbonate disposables and home dialysis segments, but uncertainties remain. Overall, the negative financial results and restructuring impact outweigh the positive outlook, leading to a negative sentiment.